The consolidation movement will cause an escalation in the number of tests for processing, which, in turn, will drive the clinical diagnostics automation market.
New analysis from Frost & Sullivan (pharma.frost.com), Brazilian Clinical Diagnostics Automation Markets, finds that the market earned revenues of $31.0 million in 2007 and estimates this to reach $49.5 million in 2012.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the Brazilian Clinical Diagnostics Automation Markets, then send an email to jjantus_pr[.]frost.com with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.
"Dealing with a massive number of samples is a time-consuming process and implies higher possibilities of error," says Tania Mito, Research Analyst at Frost & Sullivan. "Automation can alleviate this problem by optimizing the use of laboratory resources, resulting in faster and safer processes."
Moreover, in a consolidating market, automation could serve as a significant differentiation factor. Automation solutions can optimally use laboratory resources, help standardize procedures, and reduce human involvement. These competitive advantages will improve quality and speed of services, accuracy of results, and reliability of tests.
"Despite their advantages, budget restraints of the Brazilian healthcare market and the high initial investments required for automation technology has deterred several laboratories from adopting this technology," notes Mito. "In addition, end users do not fully appreciate the benefits of reduced labor requirements, since labor costs are extremely low in Brazil."
While the reduction of human resources was expected to compensate for the costs of automating laboratories in the United States and Europe, the concept of labor cost savings has not caught the fancy of investors in Brazil. Market participants can remedy this situation by promoting automation's long-term benefits such as safer and faster procedures as well as results that are more reliable.
"Automation is an excellent tool for reducing operational costs and enhancing productivity and efficiency," remarks Mito. "Processing larger quantities of samples and operating on the pre- and post-analytical stages will save costs through reductions in labor force and time, enabling the laboratory to optimize its resources."
End users should know about these advantages, if market participants wish to tap the full potential of the Brazilian market.
Brazilian Clinical Diagnostics Automation Markets is part of the Pharmaceutical & Biotechnology and of Drug Discovery Technologies & Clinical Diagnostics Growth Partnership Service programs, which also includes research in the following markets: global patient monitoring, global medical devices, global clinical diagnostics, global drug discovery technologies, and others. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Service, Growth Consulting, and Career Best Practices empower clients to create a growth focused culture that generates, evaluates, and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 30 offices on six continents.
Brazilian Clinical Diagnostics Automation Markets - N2C5